<p>This week in MDedge Cardiocast: Most tPA-eligible stroke patients <a href= "https://www.mdedge.com/cardiology/article/194199/stroke/most-us-tpa-eligible-stroke-patients-now-get-treated-within-hour"> now get treated within an hour</a>, <a href= "https://www.mdedge.com/cardiology/article/193321/stroke/laa-closure-safely-treated-af-patients-prior-ich"> LAA closure can be treated safely</a> in patients with prior hemorrhagic stroke, SGLT2 inhibitors are quickly <a href= "https://www.mdedge.com/cardiology/article/194124/heart-failure/sglt2-inhibitors-morph-hf-drugs"> morphing from diabetes to heart failure drugs</a>, and the <a href= "https://www.mdedge.com/cardiology/article/194214/cad-atherosclerosis/consider-adopting-mesa-10-year-chd-risk-calculator"> MESA cardiovascular disease risk calculator</a> can be an improvement on the ACC/AHA version.</p>

This week in MDedge Cardiocast: Most tPA-eligible stroke patients now get treated within an hour, LAA closure can be treated safely in patients with prior hemorrhagic stroke, SGLT2 inhibitors are quickly morphing from diabetes to heart failure drugs, and the MESA cardiovascular disease risk calculator can be an improvement on the ACC/AHA version.

<p>This week in MDedge Cardiocast: Most tPA-eligible stroke patients <a href="https://www.mdedge.com/cardiology/article/194199/stroke/most-us-tpa-eligible-stroke-patients-now-get-treated-within-hour" rel="noopener noreferrer"> now get treated within an hour</a>, <a href="https://www.mdedge.com/cardiology/article/193321/stroke/laa-closure-safely-treated-af-patients-prior-ich" rel="noopener noreferrer"> LAA closure can be treated safely</a> in patients with prior hemorrhagic stroke, SGLT2 inhibitors are quickly <a href="https://www.mdedge.com/cardiology/article/194124/heart-failure/sglt2-inhibitors-morph-hf-drugs" rel="noopener noreferrer"> morphing from diabetes to heart failure drugs</a>, and the <a href="https://www.mdedge.com/cardiology/article/194214/cad-atherosclerosis/consider-adopting-mesa-10-year-chd-risk-calculator" rel="noopener noreferrer"> MESA cardiovascular disease risk calculator</a> can be an improvement on the ACC/AHA version.</p>

What comes first with SGLT2 inhibitors – diabetes or heart failure?

MDedge Cardiocast is the weekly podcast from Cardiology News. The information in this podcast is provided for informational and educational purposes only.

Share What comes first with SGLT2 inhibitors – diabetes or heart failure?

Sign up to save your podcasts

What comes first with SGLT2 inhibitors – diabetes or heart failure?

What comes first with SGLT2 inhibitors – diabetes or heart failure?